S'abonner

Chronology and Determinants of Respiratory Function Changes Following Administration of Systemic Postnatal Corticosteroids in Extremely Preterm Infants - 21/11/19

Doi : 10.1016/j.jpeds.2019.07.062 
Theodore Dassios, PhD 1, 2, , Ourania Kaltsogianni, MSc 1, , Ann Hickey, MBBS 1, Ravindra Bhat, MD 1, Anne Greenough, MD 2, 3, 4
1 Neonatal Intensive Care Centre, King's College Hospital NHS Foundation Trust, London, UK 
2 Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK 
3 The Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, London, UK 
4 National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK 

Reprint requests: Theodore Dassios, PhD, NICU, Golden Jubilee Wing, Kings College Hospital, London SE5 9RS, UK.Golden Jubilee WingKings College HospitalLondonSE5 9RSUK

Abstract

Objective

To describe the effect of systemic corticosteroids administered to treat evolving bronchopulmonary dysplasia on oxygen diffusion and ventilation efficiency.

Study design

This was a retrospective cohort study of ventilated infants who received a 9-day course of dexamethasone in a tertiary neonatal unit. We calculated the transcutaneous oxygen saturation–to–fraction of inspired oxygen (FiO2) ratio (SFR), the ventilation perfusion ratio (VA/Q), and the ventilation efficiency index (VEI) before, during, and after the course of corticosteroids. The response to corticosteroids was calculated as the difference between the FiO2 percentage before starting steroids and the lowest FiO2 value during the course of steroid treatment.

Results

Seventy infants (38 males) with a median gestational age (GA) of 25.0 weeks (IQR, 24.3-26.0 weeks) and a median birth weight of 0.70 kg (IQR, 0.63-0.82 kg) were studied at a median postnatal age of 39 days (IQR, 29-48 days). The median SFR before treatment was 1.42 (IQR, 1.19-1.72), and the highest SFR was 2.35 (IQR, 1.87-2.83) after 9 days of treatment. The median VA/Q before treatment was 0.14 (IQR, 0.11-0.18) and was significantly higher at 72 hours after the start of treatment (0.22; IQR, 0.15-0.29; P < .001). The median VEI was 0.06 (IQR, 0.04-0.08) before treatment and was highest, 0.10 (IQR, 0.07-0.13) at 48 hours after starting treatment. The median rate of response to corticosteroids was 28% (IQR, 20%-37%). GA was significantly related to the response to corticosteroids (ρ = 0.283; P = .019).

Conclusions

Oxygen diffusion continues to improve throughout the entire duration of a 9-day course of systemically administered corticosteroids in ventilated extremely preterm infants. More immature infants are less responsive to corticosteroids.

Le texte complet de cet article est disponible en PDF.

Keywords : preterm-born infants, corticosteroids, respiratory function

Abbreviations : BPD, FiO2, GA, IVH, MAP, PaCO2, PDA, PMA, PVL, SFR, SpO2, VA/Q, VEI, VT


Plan


 Supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. A.G. has received grants and honoraria for lectures and consulting from Abbot Laboratories, MedImmune, and SLE (ventilator manufacturer) and currently receives a nonconditional educational grant from SLE. The other authors declare no conflicts of interest.


© 2019  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 215

P. 17-23 - décembre 2019 Retour au numéro
Article précédent Article précédent
  • 50 Years Ago in The Journal of Pediatrics : Rape: A Complex Management Problem in the Pediatric Emergency Room
  • Andreia B. Alexander, Mary A. Ott
| Article suivant Article suivant
  • Improved Neurodevelopmental Outcomes Associated with Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula: A Randomized, Controlled Trial
  • Fei Li, Steven S. Wu, Carol Lynn Berseth, Cheryl L. Harris, James D. Richards, Jennifer L. Wampler, Weihong Zhuang, Geoffrey Cleghorn, Colin D. Rudolph, Bryan Liu, D. Jill Shaddy, John Colombo

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.